From: "Jeffrey E." <[email protected]>

From: "Jeffrey E." <[email protected]> To: Subject: Re: Date: Fri, 24 Mar 2017 13:50:53 +0000 decreased by , 1 in 70? for double treatment. is it 1-200 for lower IdI. f? On Fri, Mar 24, 2017 at 9:48 AM, < > wrote: Strong LDL reduction Data with decreased cardiovascular events You saved our dear friend TRL it's really been a great pleasure working with him and you Good weekend rs Rony Shimony, M.D. F.A.C.C. Associate Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai Director, Clinical Cardiology Mount Sinai West Mount Sinai Heart 425 West 59th Street 9th Floor New York, NY 10019 Fax Cell dictated and sent from an iPhone kindly excuse typos On Mar 24, 2017, at 7:25 AM, jeffrey E. <[email protected]> wrote: thanks for the article on evolcumab, it is clear that it reduces the Idl MARKER. much less clear on its role in reduction of incidents? you were a mensch with tede please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this EFTA01051446 communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA01051447